Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen - Regional Cancer Care Associates LLC

Clinical Trials

Randomized Phase 3 study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line gemcitabine containing regimen

Type of Cancer
Pancreatic
Locations
Bethesda
Sponsor
Protocol Number
AM0010-301
Cancer Diagnosis
To Learn More Call
201-510-0910